Drops for rare and common conditions

Italian biopharmaceutical group Dompé is accelerating clinical development of recombinant human nerve growth factor (rhNGF) drops for a range of eye diseases, including neurotrophic keratitis (NK), retinitis pigmentosa (RP), dry eye syndrome and glaucoma.

In 2012, Dompé successfully developed the only human variant of NGF available for clinical assessment, produced in Escherichia coli and designed specifically for the treatment of ocular diseases.

Preliminary data from the phase I/II REPARO study, the first international clinical trial evaluating rhNGF eye drops in NK, show corneal healing in more than 70 per cent of masked subjects at eight weeks, with observed reductions in lesion size and symptom improvements (Table 1).1